Evidence map›Paper›PMID 29157215›Full record

ArticleBMC bioinformatics2017

Integration of RNA-Seq data with heterogeneous microarray data for breast cancer profiling.

Daniel Castillo, Juan Manuel Gálvez, Luis Javier Herrera, Belén San Román, Fernando Rojas, Ignacio Rojas

Abstract read
In one paragraph

Article in BMC bioinformatics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Identifying Conserved GenericJournal of fungi (Basel, Switzerland) · 2021
    Article
  19. Review
  20. Processing and Analysis of RNA-seq Data from Public Resources.Methods in molecular biology (Clifton, N.J.) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Daniel CastilloDepartment of Computer Architecture and Technology, University of Granada, Periodista Rafael Gómez Montero, 2, Granada, 18014, Spain. cased@ugr.es.ORCID http://orcid.org/0000-0002-7380-1023
Juan Manuel GálvezDepartment of Computer Architecture and Technology, University of Granada, Periodista Rafael Gómez Montero, 2, Granada, 18014, Spain.
Luis Javier HerreraDepartment of Computer Architecture and Technology, University of Granada, Periodista Rafael Gómez Montero, 2, Granada, 18014, Spain.
Belén San RománDepartment of Computer Architecture and Technology, University of Granada, Periodista Rafael Gómez Montero, 2, Granada, 18014, Spain.
Fernando RojasDepartment of Computer Architecture and Technology, University of Granada, Periodista Rafael Gómez Montero, 2, Granada, 18014, Spain.
Ignacio RojasDepartment of Computer Architecture and Technology, University of Granada, Periodista Rafael Gómez Montero, 2, Granada, 18014, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNowadays, many public repositories containing large microarray gene expression datasets are available. However, the problem lies in the fact that microarray technology are less powerful and accurate than more recent Next Generation Sequencing technologies, such as RNA-Seq. In any case, information from microarrays is truthful and robust, thus it can be exploited through the integration of microarray data with RNA-Seq data. Additionally, information extraction and acquisition of large number of samples in RNA-Seq still entails very high costs in terms of time and computational resources.This paper proposes a new model to find the gene signature of breast cancer cell lines through the integration of heterogeneous data from different breast cancer datasets, obtained from microarray and RNA-Seq technologies. Consequently, data integration is expected to provide a more robust statistical significance to the results obtained. Finally, a classification method is proposed in order to test the robustness of the Differentially Expressed Genes when unseen data is presented for diagnosis.

resultsThe proposed data integration allows analyzing gene expression samples coming from different technologies. The most significant genes of the whole integrated data were obtained through the intersection of the three gene sets, corresponding to the identified expressed genes within the microarray data itself, within the RNA-Seq data itself, and within the integrated data from both technologies. This intersection reveals 98 possible technology-independent biomarkers. Two different heterogeneous datasets were distinguished for the classification tasks: a training dataset for gene expression identification and classifier validation, and a test dataset with unseen data for testing the classifier. Both of them achieved great classification accuracies, therefore confirming the validity of the obtained set of genes as possible biomarkers for breast cancer. Through a feature selection process, a final small subset made up by six genes was considered for breast cancer diagnosis.

conclusionsThis work proposes a novel data integration stage in the traditional gene expression analysis pipeline through the combination of heterogeneous data from microarrays and RNA-Seq technologies. Available samples have been successfully classified using a subset of six genes obtained by a feature selection method. Consequently, a new classification and diagnosis tool was built and its performance was validated using previously unseen samples.

Indexed as

AlgorithmsBreast NeoplasmsCluster AnalysisDatabases, GeneticFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansOligonucleotide Array Sequence AnalysisReproducibility of ResultsSequence Analysis, RNABreast cancerCancerClassificationGene expressionIntegrationk-NNMicroarrayRandom ForestRNA-SeqSVM

Identifiers

PMID29157215
PMCPMC5697344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.